Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Compass Therapeutics ×

Compass Therapeutics

This funder is selected. Its supporting articles are shown below.

Compass Therapeutics1

Articles mentioning Compass Therapeutics

1 articles · page 1 of 1

1151 Preclinical development of CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A for the treatment of patients with cancer

jitc · abstract · 2025-11-04 · 1 matching annotations

80.4%

Compass Therapeutics endometrial carcinoma non-small cell lung cancer cervical cancer advanced renal cell carcinoma hepatocellular carcinoma CTX-10726

…over VEGF TKI-containing combination regimens. To achieve this, Compass Therapeutics is developing a novel, bispecific, tetravalent antibody that co…

Browse funders

Compass Therapeutics

Articles mentioning Compass Therapeutics

1151 Preclinical development of CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A for the treatment of patients with cancer